Status:
COMPLETED
RedStroke - Reducing Europe's Stroke Incidence
Lead Sponsor:
University Hospital, Basel, Switzerland
Collaborating Sponsors:
European Union
Preventicus GmbH
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
Phase:
NA
Brief Summary
In the RedStroke study, the effect of a smartphone application in detecting Atrial Fibrillation (AF) will be assessed in a double-blind randomised controlled multicenter trial. Outpatients with an ele...
Eligibility Criteria
Inclusion
- written informed consent
- CHA2DS2-VASc score of 3 and above, if patients are aged under 65 years
- CHA2DS2-VASc score of 2 and above, if patients are aged 65 years or older
Exclusion
- history of Atrial Fibrillation
- current anticoagulation treatment,
- cardiac implanted electronic device (ICD or/and PM)
- app cannot be installed due to technical problems (smartphone type, reduced smartphone storage capacity, other)
- inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
- enrollment of the investigator, his/her family members, employees and other dependent persons
Key Trial Info
Start Date :
October 22 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 18 2024
Estimated Enrollment :
1019 Patients enrolled
Trial Details
Trial ID
NCT04108884
Start Date
October 22 2019
End Date
January 18 2024
Last Update
May 17 2024
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medicine Greifswald
Greifswald, Mecklenburg-Vorpommern, Germany, 17475
2
Ambulantes Herz-Kreislauf-Zentrum
Pasewalk, Germany, 17309
3
Asklepeion Hospital
Athens, Attica, Greece, 17121
4
Semmelweis University - Heart and Vascular Center
Budapest, Hungary, 1122